It’s not easy to pick giant biotech winners…
But after covering the sector for 21 years, Chief Income Strategist Marc Lichtenfeld has gotten pretty good at it.
He’s closed out some big winners – like a 419% gain on Celldex Therapeutics (Nasdaq: CLDX), a 226% gain on Myovant Sciences in just two months and a more than 2,000% gain on AbbVie (NYSE: ABBV) options.
Would you like to score big gains like that?
In this week’s State of the Market, Marc outlines what he looks for to help pick big biotech winners.